Vimseltinib Patent Expiration
Vimseltinib was first introduced by Deciphera Pharmaceuticals Llc
Vimseltinib Patents
Given below is the list of patents protecting Vimseltinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Romvimza | US12509443 | Csf-1R Inhibitors And Methods Of Use Thereof | Apr 30, 2045 | Deciphera Pharms |
| Romvimza | US12686672 | Apr 30, 2045 | Deciphera Pharms | |
| Romvimza | US12447149 | Formulations Of Vimseltinib | Dec 06, 2044 | Deciphera Pharms |
| Romvimza | US12528787 | Solid State Forms Of A Kinase Inhibitor | Dec 06, 2044 | Deciphera Pharms |
| Romvimza | US12551483 | Formulations Of Vimseltinib | Dec 06, 2044 | Deciphera Pharms |
| Romvimza | US12617775 | Processes Of Making Csf-1R Inhibitors And Methods Of Use Thereof | Dec 06, 2044 | Deciphera Pharms |
| Romvimza | US12643883 | Solid State Forms Of A Kinase Inhibitor | Dec 06, 2044 | Deciphera Pharms |
| Romvimza | US11103507 | Methods of treating disorders using CSF1R inhibitors | Feb 03, 2040 | Deciphera Pharms |
| Romvimza | US11679110 | Methods of treating disorders using CSF1R inhibitors | Feb 03, 2040 | Deciphera Pharms |
| Romvimza | US12285430 | Methods of treating disorders using CSF1R inhibitors | Dec 23, 2039 | Deciphera Pharms |
| Romvimza | US12485120 | Methods Of Treating Disorders Using Csf1R Inhibitors | Dec 23, 2039 | Deciphera Pharms |
| Romvimza | US12582655 | Methods Of Treating Disorders Using Csfir Inhibitors | Dec 23, 2039 | Deciphera Pharms |
| Romvimza | US9181223 | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | Mar 14, 2034 | Deciphera Pharms |
Vimseltinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vimseltinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants | Deciphera Pharmaceuticals, LLC | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | Deciphera Pharmaceuticals, LLC | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE1, PHASE2 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor | Deciphera Pharmaceuticals, LLC | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE3 |